<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN" "http://jats.nlm.nih.gov/publishing/1.1d3/JATS-journalpublishing1.dtd">
<article article-type="research-article" dtd-version="1.1d3" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id>
<journal-title-group>
<journal-title>PLOS ONE</journal-title>
</journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, CA USA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1371/journal.pone.0163257</article-id>
<article-id pub-id-type="publisher-id">PONE-D-16-19304</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
</subj-group>
<subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancers and neoplasms</subject><subj-group><subject>Gynecological tumors</subject><subj-group><subject>Ovarian cancer</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Cell biology</subject><subj-group><subject>Chromosome biology</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Epigenetics</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Chromatin</subject><subj-group><subject>Chromatin modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>DNA</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Epigenetics</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>DNA modification</subject><subj-group><subject>DNA methylation</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Mathematical and statistical techniques</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical sciences</subject><subj-group><subject>Mathematics</subject><subj-group><subject>Statistics (mathematics)</subject><subj-group><subject>Statistical methods</subject><subj-group><subject>Meta-analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Diagnostic medicine</subject><subj-group><subject>Cancer detection and diagnosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Cancer detection and diagnosis</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Epigenetics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Molecular biology</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Artificial gene amplification and extension</subject><subj-group><subject>Polymerase chain reaction</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and analysis methods</subject><subj-group><subject>Molecular biology techniques</subject><subj-group><subject>Artificial gene amplification and extension</subject><subj-group><subject>Polymerase chain reaction</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene types</subject><subj-group><subject>Suppressor genes</subject><subj-group><subject>Tumor suppressor genes</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Oncology</subject><subj-group><subject>Carcinogenesis</subject></subj-group></subj-group></subj-group></article-categories>
<title-group>
<article-title>Association between <italic>P16<sup>INK4a</sup></italic> Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies</article-title>
<alt-title alt-title-type="running-head"><italic>P16<sup>INK4a</sup></italic> Promoter Methylation and Ovarian Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Xiao</surname>
<given-names>Xiyue</given-names>
</name>
<xref ref-type="aff" rid="aff001"><sup>1</sup></xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple">
<name name-style="western">
<surname>Cai</surname>
<given-names>Fucheng</given-names>
</name>
<xref ref-type="aff" rid="aff002"><sup>2</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Niu</surname>
<given-names>Xun</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
</contrib>
<contrib contrib-type="author" xlink:type="simple">
<name name-style="western">
<surname>Shi</surname>
<given-names>Hao</given-names>
</name>
<xref ref-type="aff" rid="aff004"><sup>4</sup></xref>
</contrib>
<contrib contrib-type="author" corresp="yes" xlink:type="simple">
<name name-style="western">
<surname>Zhong</surname>
<given-names>Yi</given-names>
</name>
<xref ref-type="aff" rid="aff003"><sup>3</sup></xref>
<xref ref-type="corresp" rid="cor001">*</xref>
</contrib>
</contrib-group>
<aff id="aff001"><label>1</label> <addr-line>Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</addr-line></aff>
<aff id="aff002"><label>2</label> <addr-line>Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</addr-line></aff>
<aff id="aff003"><label>3</label> <addr-line>Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</addr-line></aff>
<aff id="aff004"><label>4</label> <addr-line>Department of Epidemiology and Biostatistics, and the Ministry of Education Key Lab of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple">
<name name-style="western">
<surname>Williams</surname>
<given-names>Bart O.</given-names>
</name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/>
</contrib>
</contrib-group>
<aff id="edit1"><addr-line>Van Andel Institute, UNITED STATES</addr-line></aff>
<author-notes>
<fn fn-type="conflict" id="coi001">
<p>The authors have declared that no competing interests exist.</p>
</fn>
<fn fn-type="con">
<p><list list-type="simple">
<list-item><p><bold>Conceptualization:</bold> YZ XYX.</p></list-item>
<list-item><p><bold>Data curation:</bold> HS XN YZ.</p></list-item>
<list-item><p><bold>Formal analysis:</bold> XYX FCC.</p></list-item>
<list-item><p><bold>Funding acquisition:</bold> YZ FCC.</p></list-item>
<list-item><p><bold>Investigation:</bold> XYX FCC XN.</p></list-item>
<list-item><p><bold>Methodology:</bold> XYX FCC YZ.</p></list-item>
<list-item><p><bold>Project administration:</bold> YZ XYX.</p></list-item>
<list-item><p><bold>Resources:</bold> XYX XN HS.</p></list-item>
<list-item><p><bold>Software:</bold> XYX XN HS.</p></list-item>
<list-item><p><bold>Supervision:</bold> YZ.</p></list-item>
<list-item><p><bold>Validation:</bold> XYX FCC.</p></list-item>
<list-item><p><bold>Visualization:</bold> XYX YZ.</p></list-item>
<list-item><p><bold>Writing – original draft:</bold> XYX YZ.</p></list-item>
<list-item><p><bold>Writing – review &amp; editing:</bold> FCC YZ.</p></list-item>
</list></p>
</fn>
<corresp id="cor001">* E-mail: <email xlink:type="simple">zyzy0411@163.com</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>20</day>
<month>9</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>11</volume>
<issue>9</issue>
<elocation-id>e0163257</elocation-id>
<history>
<date date-type="received">
<day>17</day>
<month>5</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>9</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-year>2016</copyright-year>
<copyright-holder>Xiao et al</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="info:doi/10.1371/journal.pone.0163257"/>
<abstract>
<sec id="sec001">
<title>Background</title>
<p>Ovarian cancer is the primary cause of death in women diagnosed with gynecological malignancies worldwide. Absence of early symptoms prevents prompt diagnosis or successful therapeutic intervention. <italic>P16</italic><sup><italic>INK4a</italic></sup> is a well-known tumor suppressor gene (TSG). Aberrant methylation of TSG promoter is an important epigenetic silencing mechanism leading to ovarian cancer progression. Studies have reported differences in methylation frequencies of the <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter between ovarian cancer and the corresponding control group. However, the association between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and ovarian cancer remains unclear and controversial. Therefore, a meta-analysis was conducted to clarify the relationship between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and ovarian cancer.</p>
</sec>
<sec id="sec002">
<title>Methods</title>
<p>PubMed, Web of Science, EMBASE and CNKI were searched to identify eligible studies for the evaluation of the association between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and ovarian cancer. Odds ratio (ORs) and 95% confidence intervals (95%CI) were calculated to determine the strength of association between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and ovarian cancer.</p>
</sec>
<sec id="sec003">
<title>Results</title>
<p>A total of 612 ovarian cancer patients and 289 controls from 12 eligible studies were included in the meta-analysis. Overall, a significant association was observed between <italic>p16</italic><sup><italic>INK4a</italic></sup> methylation status and ovarian cancer risk using a fixed-effects model (OR = 2.02, 95% CI = 1.39–2.94).</p>
</sec>
<sec id="sec004">
<title>Conclusion</title>
<p>The results of our meta-analysis show that aberrant methylation of <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter was significantly associated with ovarian cancer. It may represent a promising molecular marker to monitor the disease and provides new insights into the treatment of human ovarian cancer.</p>
</sec>
</abstract>
<funding-group>
<award-group id="award001">
<funding-source>
<institution>National Nature Science Foundation of China</institution>
</funding-source>
<award-id>No. 81200745</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Zhong</surname>
<given-names>Yi</given-names>
</name>
</principal-award-recipient>
</award-group>
<award-group id="award002">
<funding-source>
<institution>National Nature Science Foundation of China</institution>
</funding-source>
<award-id>No. 81501297</award-id>
<principal-award-recipient>
<name name-style="western">
<surname>Cai</surname>
<given-names>Fucheng</given-names>
</name>
</principal-award-recipient>
</award-group>
<funding-statement>This work was supported by the National Nature Science Foundation of China (No.81200745 and No.81501297). The sponsors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement>
</funding-group>
<counts>
<fig-count count="7"/>
<table-count count="1"/>
<page-count count="12"/>
</counts>
<custom-meta-group>
<custom-meta id="data-availability">
<meta-name>Data Availability</meta-name>
<meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="sec005" sec-type="intro">
<title>Introduction</title>
<p>Ovarian cancer is the primary cause of death in women with gynecological malignancies. Based on GLOBOCAN estimates, more than 238, 700 new cancer cases were diagnosed and nearly 151,900 died from ovarian cancer worldwide in 2012 [<xref ref-type="bibr" rid="pone.0163257.ref001">1</xref>]. Absence of early symptoms prevents prompt detection or therapy of ovarian cancer. Approximately 75% of ovarian cancers are diagnosed at an advanced stage [<xref ref-type="bibr" rid="pone.0163257.ref002">2</xref>,<xref ref-type="bibr" rid="pone.0163257.ref003">3</xref>]. Therefore, early diagnosis and prevention depend on the ability to identify genetic and epigenetic events underlying the initiation and progression of the disease. Recent advances in molecular oncology have facilitated the identification and understanding of several genetic and epigenetic events that contribute to ovarian carcinogenesis [<xref ref-type="bibr" rid="pone.0163257.ref004">4</xref>–<xref ref-type="bibr" rid="pone.0163257.ref007">7</xref>].</p>
<p>Molecular genetic alterations, including activation of proto-oncogenes and inactivation of tumor suppressor genes (TSG), may play a key role in tumorigenesis. Epigenetic inactivation of genes following methylation of CpG islands in promoters is one of the most frequent events encountered in human tumors. The tumor suppressor gene <italic>p16</italic><sup><italic>INK4a</italic></sup> is a major target for carcinogenesis in various human tumors [<xref ref-type="bibr" rid="pone.0163257.ref008">8</xref>–<xref ref-type="bibr" rid="pone.0163257.ref011">11</xref>]. It is a negative regulator of cell cycle. <italic>P16</italic><sup><italic>INK4a</italic></sup> prevents the inactivation of retinoblastoma (Rb) protein by inhibiting cyclin-dependent kinases (CDks). Retinoblastoma (Rb) protein has diverse tumor-suppressor functions and plays an important role in apoptosis and cell cycle regulation [<xref ref-type="bibr" rid="pone.0163257.ref012">12</xref>]. Studies have shown that methylation of <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter may play a critical role in the development of ovarian cancer.</p>
<p>Until now, a few studies reported the differences in methylation frequencies of <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter between ovarian cancer and non-cancerous tissues. However, these findings are inconsistent. Therefore, the objectives of this meta-analysis are to consolidate the available data and to clarify the association between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and human ovarian cancer.</p>
</sec>
<sec id="sec006" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>The meta-analysis was performed according to the latest Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).</p>
<sec id="sec007">
<title>Search Strategy</title>
<p>Relevant studies were identified from online electronic databases (PubMed, Web of Science, EMBASE and CNKI) using the following key words: (ovarian OR ovary) AND (cancer OR carcinoma OR tumor) AND (<italic>p16</italic> methylation). Articles were retrieved up to May 3, 2016.</p>
</sec>
<sec id="sec008">
<title>Study Selection</title>
<p>Three independent reviewers (Xiyue Xiao, Yi Zhong, and Fucheng Cai) screened the titles and abstracts retrieved in the electronic search to identify relevant studies. The inclusion criteria were: (1) case-control study design, (2) data necessary for calculating odds ratios (ORs), (3) studies primarily evaluating the association between <italic>p16</italic><sup><italic>INK4a</italic></sup> methylation and ovarian cancer, (4) incidence of <italic>p16</italic><sup><italic>INK4a</italic></sup> methylation in both case and control groups, and (5) sample types limited to tissues. According to the inclusion criteria, the title and abstracts from the preliminary search were evaluated. All potentially relevant articles were evaluated in full. Abstracts, letters to the editor and case reports were not included. Finally, a total of 12 articles [<xref ref-type="bibr" rid="pone.0163257.ref013">13</xref>–<xref ref-type="bibr" rid="pone.0163257.ref024">24</xref>] were included in our meta-analysis involving 612 cases and 289 controls.</p>
</sec>
<sec id="sec009">
<title>Data Extraction and Quality Assessment</title>
<p>The selected studies were reviewed by three independent reviewers (Xiyue Xiao, Yi Zhong, and Fucheng Cai). The following information was extracted from the eligible studies: first author’s name, year of publication, study population, the number of people with <italic>p16</italic><sup><italic>INK4a</italic></sup> methylation in the case and control groups, the number of case and control groups, the measurement methods of methylation and control types. All the data in the included studies were checked by two reviewers (Xun Niu and Hao Shi) as described in the Cochrane Handbook for systematic reviews.</p>
</sec>
<sec id="sec010">
<title>Statistical Analysis</title>
<p>The pooled odds ratios (ORs) and their 95% confidence intervals (CIs) were calculated to assess the strength of the association between <italic>p16</italic><sup><italic>INK4a</italic></sup> methylation and ovarian cancer. Statistical heterogeneity was analyzed on the basis of <italic>I</italic>-square (<italic>I</italic><sup><italic>2</italic></sup>) value. An <italic>I</italic><sup><italic>2</italic></sup> value above 75% indicated high heterogeneity, an <italic>I</italic><sup><italic>2</italic></sup> value between 50% and 75% suggested moderate heterogeneity, and an <italic>I</italic><sup><italic>2</italic></sup> value between 25% and 50% indicated low heterogeneity. A result was homogeneous when the <italic>I</italic><sup><italic>2</italic></sup> value was less than 25%. If <italic>I</italic><sup><italic>2</italic></sup>&lt; 50%, the studies were considered homogeneous or low in heterogeneity. A fixed-effects model was used to combine the effect size. If <italic>I</italic><sup><italic>2</italic></sup>&gt; 50%, the studies were believed to be moderately or highly heterogeneous, and the random-effects model was used to combine the effect size [<xref ref-type="bibr" rid="pone.0163257.ref025">25</xref>,<xref ref-type="bibr" rid="pone.0163257.ref026">26</xref>]. A subgroup analysis was conducted to assess the impact of race (Asia and Caucasus), method (BSP and MSP), and control type (blood and tissues). Potential publication bias was assessed by Funnel plot [<xref ref-type="bibr" rid="pone.0163257.ref027">27</xref>], Begg’s test, and Egger’s test [<xref ref-type="bibr" rid="pone.0163257.ref027">27</xref>,<xref ref-type="bibr" rid="pone.0163257.ref028">28</xref>]. According to the sensitivity analysis, the contribution of each study to the final results of the meta-analysis was evaluated. All the <italic>p</italic> values were two sided with a significant level at 0.05. All statistical analyses were performed with the Meta package (version 2.2–1) in R (version 3.00).</p>
</sec>
</sec>
<sec id="sec011" sec-type="results">
<title>Results</title>
<sec id="sec012">
<title>Search Results</title>
<p>The initial search was independently executed by three reviewers (Xiyue Xiao, Yi Zhong, and Fucheng Cai), and 69 articles were initially selected. The 69 articles were quickly screened by abstract and title based on inclusion/exclusion criteria. After careful review by the three experts, 21 articles were found to be related toour meta-analysis. These articles underwent a second review. Finally, a total of 12 studies were included in the meta-analysis. The detailed steps involved in the literature search are shown in <xref ref-type="fig" rid="pone.0163257.g001">Fig 1</xref>.</p>
<fig id="pone.0163257.g001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163257.g001</object-id>
<label>Fig 1</label>
<caption>
<title>Flowchart outlining study selection in the meta-analysis.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.g001" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec013">
<title>Study Characteristics</title>
<p>Twelve studies comprising data from a total of 612 cases and 289 controls were included in this review. Eight of these studies involved Asian subjects, and four studies investigated Caucasians. Among the included studies investigating <italic>p16</italic><sup><italic>INK4a</italic></sup> methylation in ovarian cancer and controls, three utilized bisulfite sequencing PCR (BSP) and nine employed methylation-specific polymerase chain reaction (MSP). The control group included peripheral blood and tissues (benign ovarian tissues, normal ovarian tissues of cancer-free patients and adjacent tissues). Characteristics of the 12 studies are summarized in <xref ref-type="table" rid="pone.0163257.t001">Table 1</xref>.</p>
<table-wrap id="pone.0163257.t001" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163257.t001</object-id>
<label>Table 1</label> <caption><title>Characteristics of included studies.</title></caption>
<alternatives>
<graphic id="pone.0163257.t001g" mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.t001" xlink:type="simple"/>
<table>
<colgroup>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
<col align="left" valign="middle"/>
</colgroup>
<thead>
<tr>
<th align="center">Author</th>
<th align="center">Year</th>
<th align="center">Country</th>
<th align="center">Age(y)</th>
<th align="center" colspan="2">Case</th>
<th align="center" colspan="2">Control</th>
<th align="center">Method</th>
<th align="center">Case type</th>
<th align="center">Control type</th>
</tr>
<tr>
<th align="left"/>
<th align="left"/>
<th align="left"/>
<th align="left"/>
<th align="left">M</th>
<th align="left">U</th>
<th align="left">M</th>
<th align="left">U</th>
<th align="left"/>
<th align="left"/>
<th align="left"/>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Bammidi LS</td>
<td align="left">2012</td>
<td align="left">India</td>
<td align="left">20–75</td>
<td align="left">28</td>
<td align="left">22</td>
<td align="left">18</td>
<td align="left">32</td>
<td align="left">BSP</td>
<td align="left">tissues</td>
<td align="left">blood</td>
</tr>
<tr>
<td align="left">Bhagat R</td>
<td align="left">2014</td>
<td align="left">India</td>
<td align="left">20–79</td>
<td align="left">58</td>
<td align="left">76</td>
<td align="left">11</td>
<td align="left">30</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Li M</td>
<td align="left">2006</td>
<td align="left">China</td>
<td align="left">NA</td>
<td align="left">6</td>
<td align="left">12</td>
<td align="left">0</td>
<td align="left">10</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Liu Z</td>
<td align="left">2005</td>
<td align="left">USA</td>
<td align="left">27–81</td>
<td align="left">13</td>
<td align="left">39</td>
<td align="left">15</td>
<td align="left">25</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Makarla P</td>
<td align="left">2005</td>
<td align="left">USA</td>
<td align="left">51.5(20–86)</td>
<td align="left">7</td>
<td align="left">16</td>
<td align="left">3</td>
<td align="left">36</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Niederacher D</td>
<td align="left">1999</td>
<td align="left">Germany</td>
<td align="left">NA</td>
<td align="left">6</td>
<td align="left">17</td>
<td align="left">0</td>
<td align="left">10</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Shih YC</td>
<td align="left">1997</td>
<td align="left">Australia</td>
<td align="left">NA</td>
<td align="left">0</td>
<td align="left">45</td>
<td align="left">0</td>
<td align="left">2</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Tam KF</td>
<td align="left">2007</td>
<td align="left">China</td>
<td align="left">53.1±1.4</td>
<td align="left">17</td>
<td align="left">72</td>
<td align="left">5</td>
<td align="left">30</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Wong YF</td>
<td align="left">1999</td>
<td align="left">China</td>
<td align="left">NA</td>
<td align="left">2</td>
<td align="left">47</td>
<td align="left">0</td>
<td align="left">10</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">blood</td>
</tr>
<tr>
<td align="left">Shen W</td>
<td align="left">2008</td>
<td align="left">China</td>
<td align="left">52.2, 53.2</td>
<td align="left">13</td>
<td align="left">50</td>
<td align="left">0</td>
<td align="left">30</td>
<td align="left">BSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Wei W</td>
<td align="left">1999</td>
<td align="left">China</td>
<td align="left">46.5±12.47</td>
<td align="left">5</td>
<td align="left">21</td>
<td align="left">0</td>
<td align="left">2</td>
<td align="left">BSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
<tr>
<td align="left">Xu B</td>
<td align="left">2003</td>
<td align="left">China</td>
<td align="left">NA</td>
<td align="left">4</td>
<td align="left">36</td>
<td align="left">0</td>
<td align="left">20</td>
<td align="left">MSP</td>
<td align="left">tissues</td>
<td align="left">tissues</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="t001fn001"><p>Blood: peripheral blood samples from each patient with ovarian cancer; tissues: benign ovarian tissues, normal ovarian tissues of cancer-free patients and adjacent tissues; MSP: methylation-specific polymerase chain reaction; BSP: bisulfite sequencing PCR; NA: not available; M: methylation; U: unmethylation.</p></fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="sec014">
<title>Combined Analysis of Included Studies</title>
<p>The combined analysis showed the relationship between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and ovarian cancer risk (<xref ref-type="fig" rid="pone.0163257.g002">Fig 2</xref>). A fixed-effects model was employed due to low heterogeneity among the included studies (<italic>I</italic><sup><italic>2</italic></sup> = 32.1%). In the overall meta-analysis, <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation frequency was significantly associated with ovarian cancer (Summary OR was 2.02, 95%CI = 1.39–2.94).</p>
<fig id="pone.0163257.g002" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163257.g002</object-id>
<label>Fig 2</label>
<caption>
<title>Summary estimates for <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation frequency associated with ovarian cancer.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.g002" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec015">
<title>Sensitivity Analysis</title>
<p>A sensitivity analysis was performed by omitting a single study and calculating the pooled OR for the remaining studies under the fixed-effects model, to determine the effects of each individual study. The results of sensitivity analysis are summarized in <xref ref-type="fig" rid="pone.0163257.g003">Fig 3</xref>. According to sensitivity analysis, the OR ranged from 1.84 (95%CI = 1.25–2.69) to 2.68 (95%CI = 1.75–4.12) by omitting a single study in the fixed-effects model. The pooled OR values between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and ovarian cancer were reliable and stable.</p>
<fig id="pone.0163257.g003" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163257.g003</object-id>
<label>Fig 3</label>
<caption>
<title>Sensitivity analysis of pooled OR for <italic>p16</italic><sup><italic>INK4a</italic></sup> methylation and ovarian cancer under the fixed-effects model.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.g003" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec016">
<title>Subgroup Analysis</title>
<p>In the subgroup analysis based on race, the OR was 2.43 (95%CI = 1.54–3.83) in Asians, and 2.21 (95%CI = 0.34–14.34) in Caucasians (<xref ref-type="fig" rid="pone.0163257.g004">Fig 4</xref>). Subgroup analysis of the control sample showed that the frequencies of <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation in the blood group were higher than in the tissue group under the fixed-effects model (Blood: 2.16, 95%CI = 0.99–4.72; Tissues: 1.99, 95%CI = 1.30–3.04; respectively) (<xref ref-type="fig" rid="pone.0163257.g005">Fig 5</xref>). According to the mode of methylation detection for <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter, the OR was 3.00 (95%CI = 1.45–6.20) in the BSP group and 1.74 (95%CI = 1.12–2.70) in the MSP group, under the fixed-effects model (<xref ref-type="fig" rid="pone.0163257.g006">Fig 6</xref>).</p>
<fig id="pone.0163257.g004" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163257.g004</object-id>
<label>Fig 4</label>
<caption>
<title>Subgroup analysis based on race.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.g004" xlink:type="simple"/>
</fig>
<fig id="pone.0163257.g005" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163257.g005</object-id>
<label>Fig 5</label>
<caption>
<title>Subgroup analysis based on control sample type.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.g005" xlink:type="simple"/>
</fig>
<fig id="pone.0163257.g006" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163257.g006</object-id>
<label>Fig 6</label>
<caption>
<title>Subgroup analysis based on methylation detection method.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.g006" xlink:type="simple"/>
</fig>
</sec>
<sec id="sec017">
<title>Publication Bias</title>
<p>Funnel plot, Begg’s test, and Egger’s test were used to evaluate the publication bias of the studies. The funnel plot was not perfectly symmetrical (<xref ref-type="fig" rid="pone.0163257.g007">Fig 7</xref>), suggesting a slight publication bias. However, the Begg’s(P = 0.59) and Egger’s tests (P = 0.15) showed no evidence of publication bias in our meta-analysis. In addition, the ‘trim and fill’ method showed that no study required statistical correction for funnel plot asymmetry.</p>
<fig id="pone.0163257.g007" position="float">
<object-id pub-id-type="doi">10.1371/journal.pone.0163257.g007</object-id>
<label>Fig 7</label>
<caption>
<title>Funnel plot showing minor publication bias.</title>
</caption>
<graphic mimetype="image" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.g007" xlink:type="simple"/>
</fig>
</sec>
</sec>
<sec id="sec018" sec-type="conclusions">
<title>Discussion</title>
<p>The pathogenesis of human ovarian cancer involves complex, multistep and multi-factorial mechanisms including a variety of genetic and epigenetic abnormalities, signal transduction pathways, apoptosis, angiogenesis, and cell cycle regulation. Epigenetic inactivation of the tumor suppressor gene (<italic>TSG</italic>) following promoter methylation of CpG islands is one of the most frequent events in human tumors. Several studies suggest that inactivation of <italic>p16</italic><sup><italic>INK4a</italic></sup> induced by aberrant hypermethylation may play an important role in the carcinogenesis of lung, liver, stomach, breast, and uterus [<xref ref-type="bibr" rid="pone.0163257.ref029">29</xref>–<xref ref-type="bibr" rid="pone.0163257.ref033">33</xref>]. In a recent meta-analysis from six eligible studies, including 261 patients, Hu et al found that <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter hypermethylation is correlated with an increased risk of endometrial carcinoma [<xref ref-type="bibr" rid="pone.0163257.ref033">33</xref>]. Similarly, our earlier meta-analysis reported a significant hypermethylation of <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter in head and neck squamous cell carcinoma (HNSCC) [<xref ref-type="bibr" rid="pone.0163257.ref034">34</xref>].</p>
<p>The current meta-analysis investigated the association between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and human ovarian cancer. It included 12 studies comprising 612 cases and 289 controls. The pooled OR under a fixed-effects model was 2.02 (95%CI = 1.39–2.94) in the cancer cases compared with the controls. The result showed that methylation of <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter led to a 2.02-fold increased risk of human ovarian cancer compared with the control group. Begg’s tests (P = 0.59) and Egger’s tests (P = 0.15) revealed no publication bias in this study. The sensitivity analysis showed that exclusion of any single study did not affect the overall results or conclusions. Therefore, the results of our meta-analysis are reliable and show relatively strong statistical power.</p>
<p>In the subgroup analysis, the OR for was 2.43 (95%CI = 1.54–3.83) in Asians under the fixed-effects model, and 2.21 (95%CI = 0.34–14.34) in Caucasians under the random-effects model. The association between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and human ovarian cancer in Asians was stronger than in Caucasians. The findings may be attributed in large part to a combination of differences in allele frequencies and complex epistasis or gene-environment interactions [<xref ref-type="bibr" rid="pone.0163257.ref035">35</xref>]. In subgroup analysis, the OR was 3.00 (95%CI = 1.45–6.20) in the BSP group under the fixed-effects model, and 1.74 (95%CI = 1.12–2.70) in the MSP group under the fixed-effects model, respectively. In the past few years, several methods were developed to detect aberrant gene methylation (e.g., BSP, MSP, QMSP, and Pyro). MSP is a simple, sensitive, and specific method for detection of methylation status in CpG-rich regions [<xref ref-type="bibr" rid="pone.0163257.ref036">36</xref>]. However, MSP requires specific gene sequence data for the design of PCR primers, and different primers may influence the results of methylation analyses. In addition, MSP (a non-quantitative non-fluorometric PCR method) failed to detect low levels. BSP provides a more direct and quantitative analysis of most CPG sites within a defined region than MSP [<xref ref-type="bibr" rid="pone.0163257.ref037">37</xref>]. In our study, the data from both BSP and MSP methods showed that the frequency of promoter methylation in <italic>p16</italic><sup><italic>INK4a</italic></sup> was higher in ovarian cancer than in control. Subgroup analysis of the control sample type showed that the OR was 2.16 (95%CI = 0.99–4.72) in the blood group, and 1.99 (95%CI = 1.30–3.04) in the tissues, respectively, under the fixed-effects model. Subgroup analysis revealed that aberrant methylation of <italic>p</italic><sup><italic>16INK4a</italic></sup> promoter was significantly associated with ovarian cancer, regardless of race, control sample type and detection method.</p>
<p>However, potential limitations need to be considered when interpreting the results of our meta-analysis. First, since the 12 included studies were retrospective, a potential unidentified confounding, information and selection bias may exist. Second, the population size of the studies included was relatively small. Further investigations with large sample sizes are required. Additionally, we did not explore the association between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and disease characteristics (stage, metastasis, relapse and so on) in human ovarian cancer. The association between <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation and disease characteristics may highlight the unique role of <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter methylation in human ovarian cancer.</p>
<p>In conclusion, the results demonstrate that aberrant methylation of <italic>p16</italic><sup><italic>INK4a</italic></sup> promoter was associated with human ovarian cancer, suggesting that promoter methylation of <italic>p16</italic><sup><italic>INK4a</italic></sup> plays a crucial role in human ovarian cancer. It may serve as a potential biomarker for early detection and diagnosis of human ovarian cancer.</p>
</sec>
<sec id="sec019">
<title>Supporting Information</title>
<supplementary-material id="pone.0163257.s001" mimetype="application/msword" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.s001" xlink:type="simple">
<label>S1 Checklist</label>
<caption>
<title>PRISMA checklist.</title>
<p>(DOC)</p>
</caption>
</supplementary-material>
<supplementary-material id="pone.0163257.s002" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" position="float" xlink:href="info:doi/10.1371/journal.pone.0163257.s002" xlink:type="simple">
<label>S2 Checklist</label>
<caption>
<title>Meta-analysis on genetic association studies checklist.</title>
<p>(DOCX)</p>
</caption>
</supplementary-material>
</sec>
</body>
<back>
<ref-list>
<title>References</title>
<ref id="pone.0163257.ref001"><label>1</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Torre</surname> <given-names>LA</given-names></name>, <name name-style="western"><surname>Bray</surname> <given-names>F</given-names></name>, <name name-style="western"><surname>Siegel</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Ferlay</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Lortet-Tieulent</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Jemal</surname> <given-names>A</given-names></name>. <article-title>Global cancer statistics, 2012</article-title>. <source>CA Cancer J Clin</source>. <year>2015</year>; <volume>65</volume>(<issue>2</issue>):<fpage>87</fpage>–<lpage>108</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3322/caac.21262" xlink:type="simple">10.3322/caac.21262</ext-link></comment> <object-id pub-id-type="pmid">25651787</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref002"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Landis</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Murray</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Bolden</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Wingo</surname> <given-names>PA</given-names></name>. <article-title>Cancer statistics, 1998</article-title>. <source>CA Cancer J Clin</source>. <year>1998</year>; <volume>48</volume>(<issue>1</issue>):<fpage>6</fpage>–<lpage>29</lpage>. <object-id pub-id-type="pmid">9449931</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref003"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hennessy</surname> <given-names>BT</given-names></name>, <name name-style="western"><surname>Coleman</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Markman</surname> <given-names>M</given-names></name>. <article-title>Ovarian cancer</article-title>. <source>Lancet</source>. <year>2009</year>; <volume>374</volume>(<issue>9698</issue>):<fpage>1371</fpage>–<lpage>1382</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/S0140-6736(09)61338-6" xlink:type="simple">10.1016/S0140-6736(09)61338-6</ext-link></comment> <object-id pub-id-type="pmid">19793610</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref004"><label>4</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wei</surname> <given-names>SH</given-names></name>, <name name-style="western"><surname>Balch</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Paik</surname> <given-names>HH</given-names></name>, <name name-style="western"><surname>Kim</surname> <given-names>YS</given-names></name>, <name name-style="western"><surname>Baldwin</surname> <given-names>RL</given-names></name>, <name name-style="western"><surname>Liyanarachchi</surname> <given-names>S</given-names></name>, <etal>et al</etal>. <article-title>Prognostic DNA methylation biomarkers in ovarian cancer</article-title>. <source>Clin Cancer Res</source>. <year>2006</year>; <volume>12</volume>(<issue>9</issue>):<fpage>2788</fpage>–<lpage>2794</lpage>. <object-id pub-id-type="pmid">16675572</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref005"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Jones</surname> <given-names>PA</given-names></name>, <name name-style="western"><surname>Baylin</surname> <given-names>SB</given-names></name>. <article-title>The epigenomics of cancer</article-title>. <source>Cell</source>. <year>2007</year>; <volume>128</volume>(<issue>4</issue>):<fpage>683</fpage>–<lpage>692</lpage>. <object-id pub-id-type="pmid">17320506</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref006"><label>6</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Dong</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Pu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Xu</surname> <given-names>X</given-names></name>. <article-title>Frequent SLIT2 promoter methylation in the serum of patients with ovarian cancer</article-title>. <source>J Int Med Res</source>. <year>2012</year>; <volume>40</volume>(<issue>2</issue>):<fpage>681</fpage>–<lpage>686</lpage>. <object-id pub-id-type="pmid">22613430</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref007"><label>7</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Zhang</surname> <given-names>YM</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>W</given-names></name>. <article-title>The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis</article-title>. <source>J Ovarian Res</source>. <year>2016</year>; <volume>9</volume>:<fpage>23</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13048-016-0231-1" xlink:type="simple">10.1186/s13048-016-0231-1</ext-link></comment> <object-id pub-id-type="pmid">27067410</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref008"><label>8</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nobori</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Miura</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Wu</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Lois</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Takabayashi</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Carson</surname> <given-names>DA</given-names></name>. <article-title>Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers</article-title>. <source>Nature</source>. <year>1994</year>; <volume>368</volume>(<issue>6473</issue>):<fpage>753</fpage>–<lpage>756</lpage>. <object-id pub-id-type="pmid">8152487</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref009"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Okamoto</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Demetrick</surname> <given-names>DJ</given-names></name>, <name name-style="western"><surname>Spillare</surname> <given-names>EA</given-names></name>, <name name-style="western"><surname>Hagiwara</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Hussain</surname> <given-names>SP</given-names></name>, <name name-style="western"><surname>Bennett</surname> <given-names>WP</given-names></name>, <etal>et al</etal>. <article-title>Mutations and altered expression of p16INK4 in human cancer</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1994</year>; <volume>91</volume>(<issue>23</issue>):<fpage>11045</fpage>–<lpage>11049</lpage>. <object-id pub-id-type="pmid">7972006</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref010"><label>10</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kim</surname> <given-names>BN</given-names></name>, <name name-style="western"><surname>Yamamoto</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Ikeda</surname> <given-names>K</given-names></name>, <name name-style="western"><surname>Damdinsuren</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Sugita</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Ngan</surname> <given-names>CY</given-names></name>, <etal>et al</etal>. <article-title>Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues</article-title>. <source>Int J Oncol</source>. <year>2005</year>; <volume>26</volume>(<issue>5</issue>):<fpage>1217</fpage>–<lpage>1226</lpage>. <object-id pub-id-type="pmid">15809712</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref011"><label>11</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ghazizadeh</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Jin</surname> <given-names>E</given-names></name>, <name name-style="western"><surname>Shimizu</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Fujiwara</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Arai</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Ohaki</surname> <given-names>Y</given-names></name>, <etal>et al</etal>. <article-title>Role of cdk4, p16INK4, and Rb expression in the prognosis of bronchioloalveolar carcinomas</article-title>. <source>Respiration</source>. <year>2005</year>; <volume>72</volume>(<issue>1</issue>):<fpage>68</fpage>–<lpage>73</lpage>. <object-id pub-id-type="pmid">15753637</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref012"><label>12</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Assis</surname> <given-names>LV</given-names></name>, <name name-style="western"><surname>Locatelli</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Isoldi</surname> <given-names>MC</given-names></name>. <article-title>The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma</article-title>. <source>Biochim Biophys Acta</source>. <year>2014</year>; <volume>1845</volume>(<issue>2</issue>):<fpage>232</fpage>–<lpage>247</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.bbcan.2014.01.008" xlink:type="simple">10.1016/j.bbcan.2014.01.008</ext-link></comment> <object-id pub-id-type="pmid">24491449</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref013"><label>13</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bammidi</surname> <given-names>LS</given-names></name>, <name name-style="western"><surname>Neerukonda</surname> <given-names>GN</given-names></name>, <name name-style="western"><surname>Murthy</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Kanapuram</surname> <given-names>RD</given-names></name>. <article-title>p16 gene alterations in human ovarian cancers: comparison between tissue and blood samples</article-title>. <source>Int J Gynecol Cancer</source>. <year>2012</year>; <volume>22</volume>(<issue>4</issue>):<fpage>553</fpage>–<lpage>560</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/IGC.0b013e31823fa90c" xlink:type="simple">10.1097/IGC.0b013e31823fa90c</ext-link></comment> <object-id pub-id-type="pmid">22344043</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref014"><label>14</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bhagat</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Kumar</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Vaderhobli</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Premalata</surname> <given-names>CS</given-names></name>, <name name-style="western"><surname>Pallavi</surname> <given-names>VR</given-names></name>, <name name-style="western"><surname>Ramesh</surname> <given-names>G</given-names></name>, <etal>et al</etal>. <article-title>Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma</article-title>. <source>Tumour Biol</source>. <year>2014</year>; <volume>35</volume>(<issue>9</issue>):<fpage>9069</fpage>–<lpage>9078</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s13277-014-2136-1" xlink:type="simple">10.1007/s13277-014-2136-1</ext-link></comment> <object-id pub-id-type="pmid">24913706</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref015"><label>15</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Li</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Huang</surname> <given-names>ZJ</given-names></name>, <name name-style="western"><surname>Dong</surname> <given-names>WH</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>XY</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>XY</given-names></name>, <name name-style="western"><surname>He</surname> <given-names>XH</given-names></name>, <etal>et al</etal>. [<article-title>Disfigurement of p16INK4A gene expression in development of ovarian cancer and the mechanism</article-title>]. <source>Zhonghua Fu Chan Ke Za Zhi</source>. <year>2006</year>; <volume>41</volume>(<issue>6</issue>):<fpage>408</fpage>–<lpage>412</lpage>. <object-id pub-id-type="pmid">16831366</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref016"><label>16</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname> <given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>LE</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>KH</given-names></name>, <name name-style="western"><surname>Mills</surname> <given-names>GB</given-names></name>, <name name-style="western"><surname>Bondy</surname> <given-names>ML</given-names></name>, <etal>et al</etal>. <article-title>Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>; <volume>11</volume>(<issue>13</issue>):<fpage>4968</fpage>–<lpage>4976</lpage>. <object-id pub-id-type="pmid">16000597</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref017"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Makarla</surname> <given-names>PB</given-names></name>, <name name-style="western"><surname>Saboorian</surname> <given-names>MH</given-names></name>, <name name-style="western"><surname>Ashfaq</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Toyooka</surname> <given-names>KO</given-names></name>, <name name-style="western"><surname>Toyooka</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Minna</surname> <given-names>JD</given-names></name>, <etal>et al</etal>. <article-title>Promoter hypermethylation profile of ovarian epithelial neoplasms</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>; <volume>11</volume>(<issue>15</issue>):<fpage>5365</fpage>–<lpage>5369</lpage>. <object-id pub-id-type="pmid">16061849</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref018"><label>18</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Niederacher</surname> <given-names>D</given-names></name>, <name name-style="western"><surname>Yan</surname> <given-names>HY</given-names></name>, <name name-style="western"><surname>An</surname> <given-names>HX</given-names></name>, <name name-style="western"><surname>Bender</surname> <given-names>HG</given-names></name>, <name name-style="western"><surname>Beckmann</surname> <given-names>MW</given-names></name>. <article-title>CDKN2A gene inactivation in epithelial sporadic ovarian cancer</article-title>. <source>Br J Cancer</source>. <year>1999</year>; <volume>80</volume>(<issue>12</issue>):<fpage>1920</fpage>–<lpage>1926</lpage>. <object-id pub-id-type="pmid">10471040</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref019"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shen</surname> <given-names>WJ</given-names></name>, <name name-style="western"><surname>Dai</surname> <given-names>DQ</given-names></name>, <name name-style="western"><surname>Guo</surname> <given-names>KJ</given-names></name>, <name name-style="western"><surname>Li</surname> <given-names>XM</given-names></name>. [<article-title>Promoter hypermethyIation of RASSFlA, BRCAl and p16 gene in epithelial ovarian cancer and its clinical significance</article-title>]. <source>Chin J Cancer Prev Treat</source>.<year>2007</year>;<volume>15</volume>(<issue>7</issue>): <fpage>530</fpage>–<lpage>533</lpage>.</mixed-citation></ref>
<ref id="pone.0163257.ref020"><label>20</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shih</surname> <given-names>YC</given-names></name>, <name name-style="western"><surname>Kerr</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>J</given-names></name>, <name name-style="western"><surname>Hurst</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Khoo</surname> <given-names>SK</given-names></name>, <name name-style="western"><surname>Ward</surname> <given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours</article-title>. <source>Int J Cancer</source>. <year>1997</year>; <volume>70</volume>(<issue>5</issue>):<fpage>508</fpage>–<lpage>511</lpage>. <object-id pub-id-type="pmid">9052747</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref021"><label>21</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tam</surname> <given-names>KF</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>VW</given-names></name>, <name name-style="western"><surname>Liu</surname> <given-names>SS</given-names></name>, <name name-style="western"><surname>Tsang</surname> <given-names>PC</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>AN</given-names></name>, <name name-style="western"><surname>Yip</surname> <given-names>AM</given-names></name>, <etal>et al</etal>. <article-title>Methylation profile in benign, borderline and malignant ovarian tumors</article-title>. <source>J Cancer Res Clin Oncol</source>. <year>2007</year>; <volume>133</volume>(<issue>5</issue>):<fpage>331</fpage>–<lpage>341</lpage>. <object-id pub-id-type="pmid">17177027</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref022"><label>22</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wei</surname> <given-names>W</given-names></name>, <name name-style="western"><surname>Meng</surname> <given-names>ZZ</given-names></name>, <name name-style="western"><surname>Cheng</surname> <given-names>JX</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname> <given-names>JP</given-names></name>. [<article-title>Methylation of the P16 promotor in ovarian carcinoma tissues and its clinical significance</article-title>]. <source>Current Adv Obstetr Gynecol</source>. <year>1999</year>;<volume>8</volume>(<issue>2</issue>):<fpage>109</fpage>–<lpage>111</lpage>.</mixed-citation></ref>
<ref id="pone.0163257.ref023"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wong</surname> <given-names>YF</given-names></name>, <name name-style="western"><surname>Chung</surname> <given-names>TK</given-names></name>, <name name-style="western"><surname>Cheung</surname> <given-names>TH</given-names></name>, <name name-style="western"><surname>Nobori</surname> <given-names>T</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>AL</given-names></name>, <name name-style="western"><surname>Yu</surname> <given-names>J</given-names></name>, <etal>et al</etal>. <article-title>Methylation of p16INK4A in primary gynecologic malignancy</article-title>. <source>Cancer Lett</source>. <year>1999</year>; <volume>136</volume>(<issue>2</issue>):<fpage>231</fpage>–<lpage>235</lpage>. <object-id pub-id-type="pmid">10355753</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref024"><label>24</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Xu</surname> <given-names>B</given-names></name>, <name name-style="western"><surname>Dai</surname> <given-names>SZ</given-names></name>. [<article-title>Hypermethylation and its clinical significance of 5’CpG island and in p16 gene in gynecologic malignancies</article-title>]. <source>MedJQilu</source>. <year>2003</year>;<volume>18</volume>(<issue>3</issue>):<fpage>227</fpage>–<lpage>229</lpage>.</mixed-citation></ref>
<ref id="pone.0163257.ref025"><label>25</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname> <given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname> <given-names>N</given-names></name>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. <year>1986</year>; <volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>188</lpage>. <object-id pub-id-type="pmid">3802833</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref026"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Higgins</surname> <given-names>JP</given-names></name>, <name name-style="western"><surname>Thompson</surname> <given-names>SG</given-names></name>, <name name-style="western"><surname>Deeks</surname> <given-names>JJ</given-names></name>, <name name-style="western"><surname>Altman</surname> <given-names>DG</given-names></name>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ</source>. <year>2003</year>; <volume>327</volume>(<issue>7414</issue>):<fpage>557</fpage>–<lpage>560</lpage>. <object-id pub-id-type="pmid">12958120</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref027"><label>27</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Egger</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Davey Smith</surname> <given-names>G</given-names></name>, <name name-style="western"><surname>Schneider</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Minder</surname> <given-names>C</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test</article-title>. <source>BMJ</source>. <year>1997</year>; <volume>315</volume>(<issue>7109</issue>):<fpage>629</fpage>–<lpage>634</lpage>. <object-id pub-id-type="pmid">9310563</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref028"><label>28</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname> <given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname> <given-names>M</given-names></name>. <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source>. <year>1994</year>; <volume>50</volume>(<issue>4</issue>):<fpage>1088</fpage>–<lpage>1101</lpage>. <object-id pub-id-type="pmid">7786990</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref029"><label>29</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Belinsky</surname> <given-names>SA</given-names></name>, <name name-style="western"><surname>Klinge</surname> <given-names>DM</given-names></name>, <name name-style="western"><surname>Dekker</surname> <given-names>JD</given-names></name>, <name name-style="western"><surname>Smith</surname> <given-names>MW</given-names></name>, <name name-style="western"><surname>Bocklage</surname> <given-names>TJ</given-names></name>, <name name-style="western"><surname>Gilliland</surname> <given-names>FD</given-names></name>, <etal>et al</etal>. <article-title>Gene promoter methylation in plasma and sputum increases with lung cancer risk</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>; <volume>11</volume>(<issue>18</issue>):<fpage>6505</fpage>–<lpage>6511</lpage>. <object-id pub-id-type="pmid">16166426</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref030"><label>30</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hsu</surname> <given-names>LS</given-names></name>, <name name-style="western"><surname>Lee</surname> <given-names>HC</given-names></name>, <name name-style="western"><surname>Chau</surname> <given-names>GY</given-names></name>, <name name-style="western"><surname>Yin</surname> <given-names>PH</given-names></name>, <name name-style="western"><surname>Chi</surname> <given-names>CW</given-names></name>, <name name-style="western"><surname>Lui</surname> <given-names>WY</given-names></name>. <article-title>Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan</article-title>. <source>Oncol Rep</source>. <year>2006</year>; <volume>15</volume>(<issue>2</issue>):<fpage>507</fpage>–<lpage>511</lpage>. <object-id pub-id-type="pmid">16391877</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref031"><label>31</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mino</surname> <given-names>A</given-names></name>, <name name-style="western"><surname>Onoda</surname> <given-names>N</given-names></name>, <name name-style="western"><surname>Yashiro</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Aya</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Fujiwara</surname> <given-names>I</given-names></name>, <name name-style="western"><surname>Kubo</surname> <given-names>N</given-names></name>, <etal>et al</etal>. <article-title>Frequent p16 CpG island hypermethylation in primary remnant gastric cancer suggesting an independent carcinogenic pathway</article-title>. <source>Oncol Rep</source>. <year>2006</year>; <volume>15</volume>(<issue>3</issue>):<fpage>615</fpage>–<lpage>620</lpage>. <object-id pub-id-type="pmid">16465421</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref032"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Askari</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sobti</surname> <given-names>RC</given-names></name>, <name name-style="western"><surname>Nikbakht</surname> <given-names>M</given-names></name>, <name name-style="western"><surname>Sharma</surname> <given-names>SC</given-names></name>. <article-title>Promoter hypermethylation of tumour suppressor genes (p14/ARF and p16/INK4a): case-control study in North Indian population</article-title>. <source>Mol Biol Rep</source>. <year>2013</year>; <volume>40</volume>(<issue>8</issue>):<fpage>4921</fpage>–<lpage>4928</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11033-013-2592-5" xlink:type="simple">10.1007/s11033-013-2592-5</ext-link></comment> <object-id pub-id-type="pmid">23712779</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref033"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hu</surname> <given-names>ZY</given-names></name>, <name name-style="western"><surname>Tang</surname> <given-names>LD</given-names></name>, <name name-style="western"><surname>Zhou</surname> <given-names>Q</given-names></name>, <name name-style="western"><surname>Xiao</surname> <given-names>L</given-names></name>, <name name-style="western"><surname>Cao</surname> <given-names>Y</given-names></name>. <article-title>Aberrant promoter hypermethylation of p16 gene in endometrial carcinoma</article-title>. <source>Tumour Biol</source>. <year>2015</year>; <volume>36</volume>(<issue>3</issue>):<fpage>1487</fpage>–<lpage>1491</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s13277-014-2632-3" xlink:type="simple">10.1007/s13277-014-2632-3</ext-link></comment> <object-id pub-id-type="pmid">25596080</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref034"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shi</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Chen</surname> <given-names>X</given-names></name>, <name name-style="western"><surname>Lu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Gu</surname> <given-names>C</given-names></name>, <name name-style="western"><surname>Jiang</surname> <given-names>H</given-names></name>, <name name-style="western"><surname>Meng</surname> <given-names>R</given-names></name>, <etal>et al</etal>. <article-title>Association between P16INK4a promoter methylation and HNSCC: a meta-analysis of 21 published studies</article-title>. <source>PLoS One</source>. <year>2015</year>; <volume>10</volume>(<issue>4</issue>):<fpage>e0122302</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0122302" xlink:type="simple">10.1371/journal.pone.0122302</ext-link></comment> <object-id pub-id-type="pmid">25835498</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref035"><label>35</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Fraser</surname> <given-names>HB</given-names></name>, <name name-style="western"><surname>Lam</surname> <given-names>LL</given-names></name>, <name name-style="western"><surname>Neumann</surname> <given-names>SM</given-names></name>, <name name-style="western"><surname>Kobor</surname> <given-names>MS</given-names></name>. <article-title>Population-specificity of human DNA methylation</article-title>. <source>Genome Biol</source>. <year>2012</year>; <volume>13</volume>(<issue>2</issue>):<fpage>R8</fpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/gb-2012-13-2-r8" xlink:type="simple">10.1186/gb-2012-13-2-r8</ext-link></comment> <object-id pub-id-type="pmid">22322129</object-id></mixed-citation></ref>
<ref id="pone.0163257.ref036"><label>36</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Stuck</surname> <given-names>AE</given-names></name>, <name name-style="western"><surname>Rubenstein</surname> <given-names>LZ</given-names></name>, <name name-style="western"><surname>Wieland</surname> <given-names>D</given-names></name>. <article-title>Bias in meta-analysis detected by a simple, graphical test. Asymmetry detected in funnel plot was probably due to true heterogeneity</article-title>. <source>BMJ</source>. <year>1998</year>; <volume>316</volume>(<issue>7129</issue>):<fpage>469</fpage>; author reply 470–461.</mixed-citation></ref>
<ref id="pone.0163257.ref037"><label>37</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Herman</surname> <given-names>JG</given-names></name>, <name name-style="western"><surname>Graff</surname> <given-names>JR</given-names></name>, <name name-style="western"><surname>Myohanen</surname> <given-names>S</given-names></name>, <name name-style="western"><surname>Nelkin</surname> <given-names>BD</given-names></name>, <name name-style="western"><surname>Baylin</surname> <given-names>SB</given-names></name>. <article-title>Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1996</year>; <volume>93</volume>(<issue>18</issue>):<fpage>9821</fpage>–<lpage>9826</lpage>. <object-id pub-id-type="pmid">8790415</object-id></mixed-citation></ref>
</ref-list>
</back>
</article>